OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a
D967LC00001
Phase 2 small_molecule active
Quick answer
OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active